IsoRay

IsoRay FCF/Net Income

Delisted

The Free Cash Flow to Net Income Ratio of IsoRay (ISR) as of Nov 4, 2026 is 111.51 %. In the previous year, Free Cash Flow to Net Income Ratio was 100.66 % — a change of 10.78% (higher).

FCF/Net Income

111.51 %

YoY

10.78%

Last updated:

Free Cash Flow to Net Income Ratio of IsoRay is 2022 111.51 % . Free Cash Flow to Net Income Ratio of IsoRay was 2021 100.66 % . It decreases by 10.78% higher compared to the previous year.

The IsoRay FCF/Net Income history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF/Net Income
Date
FCF/Net Income
Jan 1, 2015
99.78 USD
Jan 1, 2016
92.89 USD
Jan 1, 2017
101.61 USD
Jan 1, 2018
90.28 USD
Jan 1, 2019
113.26 USD
Jan 1, 2020
119.73 USD
Jan 1, 2021
100.66 USD
Jan 1, 2022
111.51 USD
The IsoRay FCF/Net Income history
YEARFCF/Net IncomeYoY
111.51 %+10.78%
100.66 %-15.93%
119.73 %+5.72%
113.26 %+25.45%
90.28 %-11.14%
101.61 %+9.39%
92.89 %-6.91%
99.78 %+82.12%
54.79 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

IsoRay Stock analysis

What does IsoRay do? The company IsoRay Inc is a leading global company in the field of brachytherapy and specializes in the development of novel medical devices for the treatment of cancer. The company's history dates back to the 1980s when it was founded by a team of doctors and scientists. IsoRay Inc's business model is based on the research, development, and manufacturing of medical products used in the treatment of cancer. Brachytherapy is a particularly important focus. This involves a treatment method where radioactive seeds or sources are directly implanted into the tumor. The radiation destroys the cancer cells without damaging the surrounding tissue. IsoRay Inc's product range includes a variety of medical devices and accessories for conducting brachytherapy procedures. The company specializes in the development of high-tech products that enable precise and effective radiation therapy. This includes, for example, radioactive seeds that are directly implanted into the tumor or apparatuses that can selectively use radiation in specific structures of the body. A special focus of IsoRay Inc is computer-assisted planning of brachytherapy treatments. The tumor is precisely measured and the radiation sources are individually customized based on the data to achieve an optimal radiation dose. This planning is done using modern software and is an important factor for the successful treatment of cancer. In addition to research and development of medical products, IsoRay Inc also encompasses the production and distribution of these products. The company operates in more than 30 countries worldwide and collaborates closely with numerous clinics and practices to research and improve new technologies in the field of radiation therapy. One of IsoRay Inc's most well-known products is the "Cesium-131 Brachytherapy seed." This radioactive seed is particularly small and therefore ideal for targeted radiation therapy of tumors. It is used in almost all clinical areas worldwide and is considered particularly safe and effective. Other products of the company include the "Gladius™ Applicator Needle," a device for precise placement of radiation sources in tumors, as well as "Intraoperative Application Systems" that enable effective radiation therapy during surgery. Overall, IsoRay Inc is considered an innovative and successful company in the field of brachytherapy and radiation therapy. The constant development and improvement of its own products is a key factor for the company's success. High quality and close collaboration with research and practice are central to its operations. IsoRay is one of the most popular companies on Eulerpool.

Frequently Asked Questions about IsoRay stock

Free Cash Flow to Net Income Ratio of IsoRay is 111.51 % in 2022.

Free Cash Flow to Net Income Ratio of IsoRay changed from 100.66 % to 111.51 %, representing a 10.78% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Net Income Ratio IsoRay since 2006 – with annual values, charts, and detailed analysis.

The FCF/Net Income ratio measures cash flow quality. Ratios consistently above 100% suggest high-quality earnings with strong cash backing.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Net Income Ratio's IsoRay with sector peers and the industry average to assess whether it is attractive.

To evaluate Free Cash Flow to Net Income Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow to Net Income Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — IsoRay

All Key Metrics — IsoRay